DePuy sponsor’s Anika’s IDE bid for Monovisc hip treatment

Anika Therapeutics (NSDQ:ANIK) said today that DePuy Orthopedics will support its submission of an investigational device exemption to conduct a trial to expand the indication of Monovisc for the treatment of pain caused by osteoarthritis of the hip.

Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopedics are the exclusive distributors of the Monovisc in the U.S., Bedford, Mass.-based Anika Therapeutics said.

“The submission of this IDE represents an important step towards extending the benefits of Monovisc to patients living with the chronic pain associated with hip osteoarthritis, for whom non-surgical treatment options are currently limited. We believe the expanded indication will further enhance the clinical and commercial value of Monovisc, and strengthen our position in the viscosupplementation market as a leading provider of innovative and effective therapies,” CEO Dr. Charles Sherwood said in a press release.

A 560-patient study is slated covering 20 investigational sites across the U.S., with hopes of starting this year, Anika Therapeutics said.

The post DePuy sponsor’s Anika’s IDE bid for Monovisc hip treatment appeared first on MassDevice.

from MassDevice http://ift.tt/1GFOaQB